Eun Young Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eun Young Song has a total of 340 co-authors. Here are the top co-authors by number of shared publications:
Sue Shin
Department of Laboratory Medicine, Seoul National University Hospital, Seoul, Korea
27 shared publicationsEun Youn Roh
Department of Laboratory Medicine, Seoul National University College of Medicine
23 shared publicationsKyoung Un Park
Seoul Natl Univ, Dept Lab Med, Coll Med, 101 Daehak Ro, Seoul 03080, South Korea
17 shared publicationsMyoung Hee Park
Innovative Research Institute for Cell Therapy, Seoul National University College of Medicine and Hospital, Seoul, Korea
13 shared publicationsJong Hyun Yoon
Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
12 shared publications- Hajeong Lee
Transplantation Center, Seoul National University Hospital, Seoul, Republic of Korea
8 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Validation of Sequence-Specific Oligonucleotide Probe-Based HLA Homozygosity Classification Using 11-Locus Next-Generation Sequencing in Korean Cord Blood Units: Extended Haplotype Architecture and Implications for Induced Pluripotent Stem Cell Haplobanking
Sue Shin, M.D., Ph.D., Eun Young Song, M.D., Ph.D., and Eun Youn Roh, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0134
- 28 August 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Open AccessValidation of Sequence-Specific Oligonucleotide Probe-Based HLA Homozygosity Classification Using 11-Locus Next-Generation Sequencing in Korean Cord Blood Units: Extended Haplotype Architecture and Implications for Induced Pluripotent Stem Cell Haplobanking
Sue Shin, M.D., Ph.D., Eun Young Song, M.D., Ph.D., and Eun Youn Roh, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0134
- Open Access
- 20 July 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (11) , 5644-5653
Metabolic Syndrome and Its Components Are Associated with Closed-Type Endoscopic Atrophic Gastritis in a Large Screening Cohort
Purpose In recent studies, metabolic syndrome (MetS) has been identified as a risk factor for gastric cancer. To enhance risk stratification protocols and prevention for gastric cancer, we sought to determine whether MetS was associated with atrophic gastritis (AG), the premalignant lesion for gastric cancer. Methods This retrospective cross-sectional study enrolled 12,353 participants who underwent endoscopy during health check-ups between January 2015 and December 2023. Gastric mucosal atrophy was graded according to the Kimura–Takemoto classification. To minimize confounding, propensity score matching was performed using age, sex, smoking status, alcohol consumption, and H. pylori IgG serostatus. Additional analyses were restricted to participants without a history of H. pylori eradication. Results Among participants without prior H. pylori eradication, MetS was significantly associated with closed-type gastric atrophy (C2–C3) (OR 1.153, 95% CI 1.006–1.321, P = 0.041) after propensity score matching. Among the individual MetS components, abdominal obesity, hypertriglyceridemia, low HDL cholesterol, and elevated blood pressure were significantly associated with closed-type atrophy, whereas elevated fasting glucose was not. Similar findings were observed across alternative definitions of gastric atrophy (C2–O3), whereas no significant association was observed for open-type atrophy (O1–O3). Conclusion MetS and several of its components were associated with closed-type gastric atrophy (C2–C3), particularly among individuals without prior H. pylori eradication. These findings suggest that metabolic dysfunction may be associated with moderate atrophic gastric changes and support a potential role of metabolic health in gastric mucosal integrity beyond established H. pylori-related risk factors.
- 20 July 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (11) , 5644-5653
Open AccessMetabolic Syndrome and Its Components Are Associated with Closed-Type Endoscopic Atrophic Gastritis in a Large Screening Cohort
Purpose In recent studies, metabolic syndrome (MetS) has been identified as a risk factor for gastric cancer. To enhance risk stratification protocols and prevention for gastric cancer, we sought to determine whether MetS was associated with atrophic gastritis (AG), the premalignant lesion for gastric cancer. Methods This retrospective cross-sectional study enrolled 12,353 participants who underwent endoscopy during health check-ups between January 2015 and December 2023. Gastric mucosal atrophy was graded according to the Kimura–Takemoto classification. To minimize confounding, propensity score matching was performed using age, sex, smoking status, alcohol consumption, and H. pylori IgG serostatus. Additional analyses were restricted to participants without a history of H. pylori eradication. Results Among participants without prior H. pylori eradication, MetS was significantly associated with closed-type gastric atrophy (C2–C3) (OR 1.153, 95% CI 1.006–1.321, P = 0.041) after propensity score matching. Among the individual MetS components, abdominal obesity, hypertriglyceridemia, low HDL cholesterol, and elevated blood pressure were significantly associated with closed-type atrophy, whereas elevated fasting glucose was not. Similar findings were observed across alternative definitions of gastric atrophy (C2–O3), whereas no significant association was observed for open-type atrophy (O1–O3). Conclusion MetS and several of its components were associated with closed-type gastric atrophy (C2–C3), particularly among individuals without prior H. pylori eradication. These findings suggest that metabolic dysfunction may be associated with moderate atrophic gastric changes and support a potential role of metabolic health in gastric mucosal integrity beyond established H. pylori-related risk factors.
- Open Access
- 30 June 2026
- Published by Korean Association of Quality Assurance for Clinical Laboratory in Journal of Laboratory Medicine and Quality Assurance
- Vol. 48 (2) , 57-70
Development of an Algorithm for Interpretation of HLA Single-Antigen Bead–Based Antibody Identification Test and Report Form
- 30 June 2026
- Published by Korean Association of Quality Assurance for Clinical Laboratory in Journal of Laboratory Medicine and Quality Assurance
- Vol. 48 (2) , 57-70
Open AccessDevelopment of an Algorithm for Interpretation of HLA Single-Antigen Bead–Based Antibody Identification Test and Report Form
- Open Access
- 23 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1878975
Intragraft donor-specific antibodies reflect histologic heterogeneity in kidney allografts with concurrent serum DSA
Background: Circulating donor-specific antibodies (sDSA) are clinically important markers of alloimmune risk, but their presence or strength does not always correspond to concurrent antibody-mediated rejection (ABMR) in kidney transplantation. We investigated whether intragraft donor-specific antibodies (gDSA) detected in kidney biopsy eluates are associated with histologic findings in recipients with concurrent sDSA positivity. Methods: All available frozen kidney biopsies in recipients with concurrent weak to moderate sDSA at Seoul National University Hospital between January 2020 and June 2024 were included. Sixty biopsy eluates from 60 patients were tested using a Luminex single antigen bead assay and analyzed according to biopsy findings. Results: The prevalence of gDSA differed significantly across histologic diagnoses (overall P = 3.3 × 10 -4 ), with higher positivity in C4d-only lesions (100.0%), aABMR (90.9%) and aABMR+TCMR (83.3%), whereas lower frequencies were observed in caABMR (44.4%), no rejection (22.7%), and aTCMR (14.3%). The gDSA positive rate in aABMR was significantly higher than that in the no-rejection group (corrected P = 0.003; OR 34, 95% CI 3.5–334). The MFI sum of gDSA was significantly higher in aABMR, aABMR+TCMR, and C4d-only lesions (corrected P = 0.009, 0.035, and 0.007, respectively). In contrast, the sum of sDSA MFI did not differ significantly across the histologic groups. Conclusions: In kidney transplant recipients with concurrent sDSA, the presence and intensity of gDSA varied according to biopsy-proven histologic findings, most prominently in aABMR and related lesions. These findings suggest that gDSA may provide additional tissue-level immunologic context for understanding histologic heterogeneity among kidney transplant recipients with circulating sDSA.
- 23 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1878975
Open AccessIntragraft donor-specific antibodies reflect histologic heterogeneity in kidney allografts with concurrent serum DSA
Background: Circulating donor-specific antibodies (sDSA) are clinically important markers of alloimmune risk, but their presence or strength does not always correspond to concurrent antibody-mediated rejection (ABMR) in kidney transplantation. We investigated whether intragraft donor-specific antibodies (gDSA) detected in kidney biopsy eluates are associated with histologic findings in recipients with concurrent sDSA positivity. Methods: All available frozen kidney biopsies in recipients with concurrent weak to moderate sDSA at Seoul National University Hospital between January 2020 and June 2024 were included. Sixty biopsy eluates from 60 patients were tested using a Luminex single antigen bead assay and analyzed according to biopsy findings. Results: The prevalence of gDSA differed significantly across histologic diagnoses (overall P = 3.3 × 10 -4 ), with higher positivity in C4d-only lesions (100.0%), aABMR (90.9%) and aABMR+TCMR (83.3%), whereas lower frequencies were observed in caABMR (44.4%), no rejection (22.7%), and aTCMR (14.3%). The gDSA positive rate in aABMR was significantly higher than that in the no-rejection group (corrected P = 0.003; OR 34, 95% CI 3.5–334). The MFI sum of gDSA was significantly higher in aABMR, aABMR+TCMR, and C4d-only lesions (corrected P = 0.009, 0.035, and 0.007, respectively). In contrast, the sum of sDSA MFI did not differ significantly across the histologic groups. Conclusions: In kidney transplant recipients with concurrent sDSA, the presence and intensity of gDSA varied according to biopsy-proven histologic findings, most prominently in aABMR and related lesions. These findings suggest that gDSA may provide additional tissue-level immunologic context for understanding histologic heterogeneity among kidney transplant recipients with circulating sDSA.
- 9 June 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Reemerging kidney paired donation in Korea: simultaneous two-way swaps to overcome human leukocyte antigen and anatomic barriers
South Korea first implemented kidney paired donation (KPD) to overcome ABO-incompatible living-donor kidney transplantation. Although utilization declined as desensitization matured, persistent desensitization failure and anatomic constraints have renewed interest in KPD within a regulated framework. We report a recent single-center experience. KPD exchanges were coordinated within an institutional registry under national supervision. We retrospectively reviewed six consecutive, simultaneous two-way exchanges (12 recipients) from 2022 to 2025. We assessed predefined desensitization failure or anticipated failure with the intended donor, compared immunologic compatibility between intended and exchange donors, and recorded perioperative desensitization, graft function, delayed graft function (DGF), and biopsy-proven acute rejection (BPAR). Five of six exchanges were undertaken for immunologic reasons. All five met criteria for desensitization failure or anticipated failure to the intended donor, with positive crossmatch and high donor-specific antibody (DSA) burden. Reassignment to the exchange donor reduced risk, lowering maximum DSA mean fluorescence intensity (MFI) from 13,228 to 1,350 and total DSA MFI from 20,542 to 2,240, although selective desensitization was still required in some recipients with residual human leukocyte antigen or ABO incompatibility. The remaining exchange addressed an anatomic constraint (adult-pediatric size mismatch). At a median follow-up of 12.2 months (range, 0.9-42.1 months), no DGF or BPAR occurred; all grafts were functioning, and the median estimated glomerular filtration rate was 66.8 mL/min/1.73 m2 . KPD is a safe alternative when desensitization fails or is predicted to fail, including in highly sensitized and anatomically complex candidates. These findings support renewed implementation of KPD alongside selective desensitization in Korea.
- 9 June 2026
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
Reemerging kidney paired donation in Korea: simultaneous two-way swaps to overcome human leukocyte antigen and anatomic barriers
South Korea first implemented kidney paired donation (KPD) to overcome ABO-incompatible living-donor kidney transplantation. Although utilization declined as desensitization matured, persistent desensitization failure and anatomic constraints have renewed interest in KPD within a regulated framework. We report a recent single-center experience. KPD exchanges were coordinated within an institutional registry under national supervision. We retrospectively reviewed six consecutive, simultaneous two-way exchanges (12 recipients) from 2022 to 2025. We assessed predefined desensitization failure or anticipated failure with the intended donor, compared immunologic compatibility between intended and exchange donors, and recorded perioperative desensitization, graft function, delayed graft function (DGF), and biopsy-proven acute rejection (BPAR). Five of six exchanges were undertaken for immunologic reasons. All five met criteria for desensitization failure or anticipated failure to the intended donor, with positive crossmatch and high donor-specific antibody (DSA) burden. Reassignment to the exchange donor reduced risk, lowering maximum DSA mean fluorescence intensity (MFI) from 13,228 to 1,350 and total DSA MFI from 20,542 to 2,240, although selective desensitization was still required in some recipients with residual human leukocyte antigen or ABO incompatibility. The remaining exchange addressed an anatomic constraint (adult-pediatric size mismatch). At a median follow-up of 12.2 months (range, 0.9-42.1 months), no DGF or BPAR occurred; all grafts were functioning, and the median estimated glomerular filtration rate was 66.8 mL/min/1.73 m2 . KPD is a safe alternative when desensitization fails or is predicted to fail, including in highly sensitized and anatomically complex candidates. These findings support renewed implementation of KPD alongside selective desensitization in Korea.
- Open Access
- 8 June 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (4) , 360-361
Toward a More Complete High-Resolution Human Leukocyte Antigen Reference for Koreans
- 8 June 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (4) , 360-361
Open AccessToward a More Complete High-Resolution Human Leukocyte Antigen Reference for Koreans
- Open Access
- 25 May 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (13) , e70264
Longitudinal Changes in the Serum Pepsinogen I/ II Ratio With Progression of Gastric Atrophy
Background: This study evaluated longitudinal changes in the serum pepsinogen (PG) I/II ratio according to endoscopic gastric mucosal atrophy. Methods: We retrospectively analyzed 21,265 participants who underwent endoscopy during health checkups between 2015 and 2023. Longitudinal changes in PG I/II ratio were examined in 2217 subjects with ≥ 2 endoscopies using linear mixed‐effects models. Serum PG I, PG II, and Helicobacter pylori IgG were measured. The AG severity was graded endoscopically according to Kimura–Takemoto classification. Results: The PG I/II ratio decreased stepwise with advancing Kimura‐Takemoto stage. In longitudinal analyses of 2217 participants with repeated endoscopy, within‐subject declines in the PG I/II ratio paralleled progression of endoscopic atrophy, with greater reductions in more advanced stages (No atrophy: reference; C2: −0.383; C3: −1.150; O1: −1.412; O2: −2.101; O3: −2.007; all p < 0.001). Conclusions: Within‐subject declines in the PG I/II ratio were observed with progression of gastric atrophy. Serial measurement of the PG I/II ratio may be useful for monitoring the progression of gastric mucosal atrophy, particularly in patients for whom repeated endoscopic evaluation is not feasible.
- 25 May 2026
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 40 (13) , e70264
Open AccessLongitudinal Changes in the Serum Pepsinogen I/ II Ratio With Progression of Gastric Atrophy
Background: This study evaluated longitudinal changes in the serum pepsinogen (PG) I/II ratio according to endoscopic gastric mucosal atrophy. Methods: We retrospectively analyzed 21,265 participants who underwent endoscopy during health checkups between 2015 and 2023. Longitudinal changes in PG I/II ratio were examined in 2217 subjects with ≥ 2 endoscopies using linear mixed‐effects models. Serum PG I, PG II, and Helicobacter pylori IgG were measured. The AG severity was graded endoscopically according to Kimura–Takemoto classification. Results: The PG I/II ratio decreased stepwise with advancing Kimura‐Takemoto stage. In longitudinal analyses of 2217 participants with repeated endoscopy, within‐subject declines in the PG I/II ratio paralleled progression of endoscopic atrophy, with greater reductions in more advanced stages (No atrophy: reference; C2: −0.383; C3: −1.150; O1: −1.412; O2: −2.101; O3: −2.007; all p < 0.001). Conclusions: Within‐subject declines in the PG I/II ratio were observed with progression of gastric atrophy. Serial measurement of the PG I/II ratio may be useful for monitoring the progression of gastric mucosal atrophy, particularly in patients for whom repeated endoscopic evaluation is not feasible.
- Open Access
- 17 April 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (4) , 362-376
Advances in HLA and Non-HLA Immune Profiling: Integrating Next-Generation Sequencing and Artificial Intelligence in Transplantation
Eunji Shin , Ph.D., Eun Young Song , M.D., Ph.D., Eun-Suk Kang , M.D., Ph.D., and Minjeong Nam , M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0636
- 17 April 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (4) , 362-376
Open AccessAdvances in HLA and Non-HLA Immune Profiling: Integrating Next-Generation Sequencing and Artificial Intelligence in Transplantation
Eunji Shin , Ph.D., Eun Young Song , M.D., Ph.D., Eun-Suk Kang , M.D., Ph.D., and Minjeong Nam , M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0636
- Open Access
- 30 September 2025
- Published by The Korean Society for Transplantation in Clinical Transplantation and Research
- Vol. 39 (3) , 259-268
Status quo of histocompatibility testing and prospects for virtual crossmatching within the Korean kidney allocation system: survey of laboratory directors
John Jeongseok Yang, Borae G Park, Hyun-Woo Choi, Eun Young Song, Jaeseok Yang, Jae Berm Park, Eun-Suk Kang. Clin Transplant Res 2025;39:259-68. https://doi.org/10.4285/ctr.25.0058
- 30 September 2025
- Published by The Korean Society for Transplantation in Clinical Transplantation and Research
- Vol. 39 (3) , 259-268
Open AccessStatus quo of histocompatibility testing and prospects for virtual crossmatching within the Korean kidney allocation system: survey of laboratory directors
John Jeongseok Yang, Borae G Park, Hyun-Woo Choi, Eun Young Song, Jaeseok Yang, Jae Berm Park, Eun-Suk Kang. Clin Transplant Res 2025;39:259-68. https://doi.org/10.4285/ctr.25.0058